ERBB2 and neoplasm: The functional significance of these observations are brought home by the finding that a number of patients treated with and responding to trastuzumab were found in a subsequent centralised review to be false positive for HER2 in the primary tumour, suggesting that their disseminated disease may have gained HER2 expression [263].